Fractyl Health Reports Positive Results for Revita Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 04 2026
0mins
Source: Newsfilter
- Significant Weight Maintenance: Participants maintained approximately 78% of their weight loss after a single Revita procedure following GLP-1 therapy cessation, highlighting Revita's potential as a new solution for obesity treatment.
- Continued Weight Loss: One year post-Revita treatment, 33% of participants continued to lose weight, indicating the procedure's effectiveness in long-term weight management and the potential to reshape current obesity treatment strategies.
- Good Safety Profile: Among 22 participants, no serious adverse events were reported, with mild adverse reactions occurring in 36%, all transient, suggesting Revita's excellent tolerability for broader application.
- Future Data Outlook: Fractyl plans to release randomized data from the REMAIN-1 Midpoint Cohort in Q3 2026 and topline results from the REMAIN-1 Pivotal Cohort in Q4 2026, further validating Revita's clinical efficacy and market potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GUTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GUTS
Wall Street analysts forecast GUTS stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.850
Low
2.00
Averages
5.00
High
8.00
Current: 0.850
Low
2.00
Averages
5.00
High
8.00
About GUTS
Fractyl Health, Inc. is a metabolic therapeutics company. The Company is focused on developing new approaches to the treatment of metabolic diseases, including obesity and type 2 diabetes (T2D). The Company’s lead product candidate, Revita, is designed to remodel the duodenal lining via hydrothermal ablation (i.e. duodenal mucosal resurfacing) to reverse damage to intestinal nutrient sensing and signaling mechanisms caused by chronic high-fat and high-sugar diets that are a root cause of metabolic disease. The Revita clinical program is focused on patients living with obesity who want to maintain their weight loss after GLP-1 drug discontinuation. The Company’s Rejuva platform focuses on developing adeno-associated virus (AAV)-based, locally delivered gene therapies for the treatment of obesity and T2D. The Rejuva platform leverages advanced delivery systems and proprietary screening methods to identify and develop metabolically active gene therapy candidates targeting the pancreas.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Fractyl Health Reports Positive One-Year Results for Revita
- Clinical Trial Results: Fractyl Health's REVEAL-1 Cohort study results indicate that participants who underwent the Revita procedure maintained approximately 78% of their weight loss one year after stopping GLP-1 therapy, demonstrating the therapy's effectiveness in weight maintenance.
- Stable Weight Changes: Participants exhibited a mean total body weight change of 5.3% ± 2.1% over the year, with all patients maintaining at least 5% of their GLP-1-induced weight loss, highlighting Revita's potential in long-term weight management.
- Good Safety Profile: No procedure-related serious adverse events or new treatment-emergent adverse events were observed during the study, further enhancing the therapy's safety and acceptability.
- Future Data Expectations: Fractyl anticipates reporting one-year data from the REMAIN-1 Midpoint Cohort in Q3 2026, followed by topline six-month data from the REMAIN-1 Pivotal Cohort in early Q4 2026, showcasing the company's ongoing commitment to future research.
See More
Fractyl Health Reports Positive Results for Revita Treatment
- Significant Weight Maintenance: Participants maintained approximately 78% of their weight loss after a single Revita procedure following GLP-1 therapy cessation, highlighting Revita's potential as a new solution for obesity treatment.
- Continued Weight Loss: One year post-Revita treatment, 33% of participants continued to lose weight, indicating the procedure's effectiveness in long-term weight management and the potential to reshape current obesity treatment strategies.
- Good Safety Profile: Among 22 participants, no serious adverse events were reported, with mild adverse reactions occurring in 36%, all transient, suggesting Revita's excellent tolerability for broader application.
- Future Data Outlook: Fractyl plans to release randomized data from the REMAIN-1 Midpoint Cohort in Q3 2026 and topline results from the REMAIN-1 Pivotal Cohort in Q4 2026, further validating Revita's clinical efficacy and market potential.
See More
Fractyl Health (GUTS) Q1 2026 Earnings Call Insights
- Financial Recovery: Fractyl Health reported a net income of $9.2 million for Q1 2026, a significant improvement from a net loss of $43.7 million in Q4 2025, although this shift was primarily driven by a non-cash accounting adjustment, indicating a need for cautious interpretation of operational performance.
- R&D Progress: The REMAIN-1 pivotal cohort has completed randomizations with over 300 participants in the U.S., maintaining a participant retention rate exceeding 90%, and the company is on track to deliver 6-month primary endpoint data in early Q4 2026, which could enhance investor confidence.
- Accelerated Regulatory Pathway: The recently announced RAPID coverage pathway by CMS and FDA is expected to materially derisk and potentially accelerate the commercialization reimbursement timeline for Revita, thereby strengthening the company's competitive position in the market.
- New Drug Candidate Approval: Fractyl Health has received authorization from EU regulatory authorities to initiate the Phase I/II study of the RJVA-001 drug candidate, with preliminary data expected in the second half of 2026, marking a significant milestone in the company's drug development efforts.
See More
Avaí Bio Initiates α-Klotho Cell Production Phase
- Market Growth Potential: The global cell therapy manufacturing market is projected to exceed $7 billion in 2026 and reach $14 billion by 2035, indicating strong growth momentum that drives strategic positioning for companies like Avaí Bio.
- Regulatory Flexibility Enhancement: The FDA's easing of manufacturing requirements for cell and gene therapies accelerates the approval timeline for life-saving products, creating a historic shift that provides companies with scalable bioproduction infrastructure and enhances market competitiveness.
- Cell Bank Development: Avaí Bio, in partnership with Austrianova, has begun manufacturing a Master Cell Bank (MCB) for α-Klotho protein, establishing a stable production foundation that ensures product quality and consistency for future cell therapies.
- Clinical Trial Outlook: The production of α-Klotho cells will directly support Austrianova's Cell-in-a-Box® platform, aiming to provide patients with durable anti-aging treatments, marking a significant advancement for the company in addressing aging-related diseases.
See More
Global Cell Therapy Market Reaches Inflection Point with $7 Billion Projection
- Market Growth: The global cell therapy manufacturing market is projected to exceed $7 billion in 2026 and reach $14 billion by 2035, indicating robust growth potential that drives demand for cell and gene therapies.
- FDA Regulatory Impact: The FDA's easing of manufacturing requirements accelerates the approval timeline for life-saving products, creating sustainable value for therapy developers like Avaí Bio, marking a historic shift in the industry.
- Strategic Production Capacity: As biologics production capacity becomes a coveted strategic asset, Avaí Bio and Austrianova have commenced manufacturing a Master Cell Bank of α-Klotho protein, ensuring high quality and consistency for future production.
- Innovative Technology Application: Avaí Bio's cell therapy products will be developed using the Cell-in-a-Box® encapsulation platform, aiming to provide durable anti-aging treatments for patients, signifying the company's successful pivot into biotechnology.
See More
Fractyl Health Q4 2025 Earnings Report Analysis
- Financial Overview: Fractyl Health Inc reported a net loss of $43.7 million for Q4 2025, significantly up from $25 million in Q4 2024, indicating pressure on cost control that may impact future funding capabilities.
- R&D and Operating Expenses: Research and development expenses were $16.5 million, down from $20.3 million in Q4 2024, reflecting a cautious approach to R&D investment, while SG&A expenses rose to $6.8 million, increasing operational burdens.
- Cash Flow and Funding Outlook: As of December 31, 2025, the company had approximately $81.5 million in cash and cash equivalents, expected to fund operations into early 2027, providing some financial flexibility despite economic pressures.
- FDA Feedback and Market Opportunity: Fractyl Health received favorable feedback from the FDA regarding the Revita device, indicating potential Class II device classification, which, combined with a growing market demand, could provide strong support for the company's future commercialization efforts.
See More
Fractyl Health Reports Positive One-Year Results for Revita
- Clinical Trial Results: Fractyl Health's REVEAL-1 Cohort study results indicate that participants who underwent the Revita procedure maintained approximately 78% of their weight loss one year after stopping GLP-1 therapy, demonstrating the therapy's effectiveness in weight maintenance.
- Stable Weight Changes: Participants exhibited a mean total body weight change of 5.3% ± 2.1% over the year, with all patients maintaining at least 5% of their GLP-1-induced weight loss, highlighting Revita's potential in long-term weight management.
- Good Safety Profile: No procedure-related serious adverse events or new treatment-emergent adverse events were observed during the study, further enhancing the therapy's safety and acceptability.
- Future Data Expectations: Fractyl anticipates reporting one-year data from the REMAIN-1 Midpoint Cohort in Q3 2026, followed by topline six-month data from the REMAIN-1 Pivotal Cohort in early Q4 2026, showcasing the company's ongoing commitment to future research.
See More
Fractyl Health Reports Positive Results for Revita Treatment
- Significant Weight Maintenance: Participants maintained approximately 78% of their weight loss after a single Revita procedure following GLP-1 therapy cessation, highlighting Revita's potential as a new solution for obesity treatment.
- Continued Weight Loss: One year post-Revita treatment, 33% of participants continued to lose weight, indicating the procedure's effectiveness in long-term weight management and the potential to reshape current obesity treatment strategies.
- Good Safety Profile: Among 22 participants, no serious adverse events were reported, with mild adverse reactions occurring in 36%, all transient, suggesting Revita's excellent tolerability for broader application.
- Future Data Outlook: Fractyl plans to release randomized data from the REMAIN-1 Midpoint Cohort in Q3 2026 and topline results from the REMAIN-1 Pivotal Cohort in Q4 2026, further validating Revita's clinical efficacy and market potential.
See More
Fractyl Health (GUTS) Q1 2026 Earnings Call Insights
- Financial Recovery: Fractyl Health reported a net income of $9.2 million for Q1 2026, a significant improvement from a net loss of $43.7 million in Q4 2025, although this shift was primarily driven by a non-cash accounting adjustment, indicating a need for cautious interpretation of operational performance.
- R&D Progress: The REMAIN-1 pivotal cohort has completed randomizations with over 300 participants in the U.S., maintaining a participant retention rate exceeding 90%, and the company is on track to deliver 6-month primary endpoint data in early Q4 2026, which could enhance investor confidence.
- Accelerated Regulatory Pathway: The recently announced RAPID coverage pathway by CMS and FDA is expected to materially derisk and potentially accelerate the commercialization reimbursement timeline for Revita, thereby strengthening the company's competitive position in the market.
- New Drug Candidate Approval: Fractyl Health has received authorization from EU regulatory authorities to initiate the Phase I/II study of the RJVA-001 drug candidate, with preliminary data expected in the second half of 2026, marking a significant milestone in the company's drug development efforts.
See More
Avaí Bio Initiates α-Klotho Cell Production Phase
- Market Growth Potential: The global cell therapy manufacturing market is projected to exceed $7 billion in 2026 and reach $14 billion by 2035, indicating strong growth momentum that drives strategic positioning for companies like Avaí Bio.
- Regulatory Flexibility Enhancement: The FDA's easing of manufacturing requirements for cell and gene therapies accelerates the approval timeline for life-saving products, creating a historic shift that provides companies with scalable bioproduction infrastructure and enhances market competitiveness.
- Cell Bank Development: Avaí Bio, in partnership with Austrianova, has begun manufacturing a Master Cell Bank (MCB) for α-Klotho protein, establishing a stable production foundation that ensures product quality and consistency for future cell therapies.
- Clinical Trial Outlook: The production of α-Klotho cells will directly support Austrianova's Cell-in-a-Box® platform, aiming to provide patients with durable anti-aging treatments, marking a significant advancement for the company in addressing aging-related diseases.
See More
Global Cell Therapy Market Reaches Inflection Point with $7 Billion Projection
- Market Growth: The global cell therapy manufacturing market is projected to exceed $7 billion in 2026 and reach $14 billion by 2035, indicating robust growth potential that drives demand for cell and gene therapies.
- FDA Regulatory Impact: The FDA's easing of manufacturing requirements accelerates the approval timeline for life-saving products, creating sustainable value for therapy developers like Avaí Bio, marking a historic shift in the industry.
- Strategic Production Capacity: As biologics production capacity becomes a coveted strategic asset, Avaí Bio and Austrianova have commenced manufacturing a Master Cell Bank of α-Klotho protein, ensuring high quality and consistency for future production.
- Innovative Technology Application: Avaí Bio's cell therapy products will be developed using the Cell-in-a-Box® encapsulation platform, aiming to provide durable anti-aging treatments for patients, signifying the company's successful pivot into biotechnology.
See More
Fractyl Health Q4 2025 Earnings Report Analysis
- Financial Overview: Fractyl Health Inc reported a net loss of $43.7 million for Q4 2025, significantly up from $25 million in Q4 2024, indicating pressure on cost control that may impact future funding capabilities.
- R&D and Operating Expenses: Research and development expenses were $16.5 million, down from $20.3 million in Q4 2024, reflecting a cautious approach to R&D investment, while SG&A expenses rose to $6.8 million, increasing operational burdens.
- Cash Flow and Funding Outlook: As of December 31, 2025, the company had approximately $81.5 million in cash and cash equivalents, expected to fund operations into early 2027, providing some financial flexibility despite economic pressures.
- FDA Feedback and Market Opportunity: Fractyl Health received favorable feedback from the FDA regarding the Revita device, indicating potential Class II device classification, which, combined with a growing market demand, could provide strong support for the company's future commercialization efforts.
See More
